Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Planning To Solicit Information Aimed At Cutting Needlestick Risk

This article was originally published in The Gray Sheet

Executive Summary

FDA plans to issue an advance notice of proposed rulemaking (ANPRM) to collect information on further steps to reduce the risk of needlestick injuries, the agency announced Sept 5. The advance notice will seek comments on whether FDA should develop a standard for devices that may cause sharps injury.

You may also be interested in...



BD’s Sharp Thinking: Transition From Traditional Needle-Bearing Devices

Becton Dickinson's decision to discontinue sales of its conventional Insyte IV catheters beginning in September is indicative of a trend away from standard needle-bearing offerings in the U.S. in favor of safety-engineered designs

BD’s Sharp Thinking: Transition From Traditional Needle-Bearing Devices

Becton Dickinson's decision to discontinue sales of its conventional Insyte IV catheters beginning in September is indicative of a trend away from standard needle-bearing offerings in the U.S. in favor of safety-engineered designs

OSHA Regs Will Not Keep Unsafe Sharps From Workplace - HRG Petition

FDA should remove from the market all blood collection devices and I.V. catheters for which safer alternatives exist, Public Citizen's Health Research Group is urging in a Nov. 29 petition to Commissioner Jane Henney.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015398

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel